We also discovered a novel synergistic combination of IB with the STAT5 inhibitor pimozide which effectively targets FLT3/ITD+ AML while sparing cell lines without the mutation and sparing CD34+ cord blood cells. Here, CD34 is linked to acute myeloid leukemia.